Processa Pharmaceuticals, Inc.
PCSA
$0.26
-$0.01-2.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.33% | 2.82% | 6.91% | -15.65% | -31.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.48% | 23.07% | 18.97% | 5.19% | -20.30% |
| Operating Income | -10.48% | -23.07% | -18.97% | -5.19% | 20.30% |
| Income Before Tax | -12.21% | -26.00% | -21.70% | -6.55% | 46.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.21% | -26.00% | -21.70% | -6.55% | 46.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.21% | -26.00% | -21.70% | -6.55% | 46.95% |
| EBIT | -10.48% | -23.07% | -18.97% | -5.19% | 20.30% |
| EBITDA | -10.48% | -23.06% | -21.32% | -8.93% | 16.98% |
| EPS Basic | 71.17% | 55.99% | 50.48% | 55.00% | 78.73% |
| Normalized Basic EPS | 71.17% | 55.99% | 50.48% | 55.00% | 65.30% |
| EPS Diluted | 71.17% | 55.99% | 50.48% | 55.00% | 78.73% |
| Normalized Diluted EPS | 71.17% | 55.99% | 50.48% | 55.00% | 65.30% |
| Average Basic Shares Outstanding | 651.23% | 288.41% | 193.61% | 133.33% | 117.53% |
| Average Diluted Shares Outstanding | 651.23% | 288.41% | 193.61% | 133.33% | 117.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |